Form 4: Cabaletta Bio Director Receives Stock Option Grant

Director Mark Simon was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Summary

• Director Mark Simon received a grant of 22,000 stock options for Cabaletta Bio, Inc. (CABA) common stock.
• The options have an exercise price of $3.22 per share.
• The grant date for the transaction was June 9, 2026.
• The options are scheduled to vest in full on the earlier of June 9, 2027, or the date of the next annual stockholders' meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $3.22 exercise price.

Future Outlook

The options vest in one year or upon the next annual meeting, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical non-employee director compensation packages for small-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 9, 2027, or the next annual stockholders' meeting.

Key Dates

Keywords

Cabaletta Bio, CABA, Form 4, Insider Trading, Stock Options, Director Compensation